Trial Profile

A clinical trial of dual EZH1/2 (polycomb repressive complex 2 subunits) inhibitor: Phase I investigator-initiated study in pediatric, adolescent and young adult patient with malignant solid tumors (ELEPHANT trial)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valemetostat (Primary)
Indications Chordoma; Glioma; Neuroblastoma; Rhabdoid tumour; Solid tumours; Teratoma
Focus Adverse reactions
Acronyms ELEPHANT trial
Sponsors Daiichi Sankyo Company

12 Jul 2022 New trial record
07 Jun 2022 According to the trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology, enrollment into the dose escalation cohort was completed.
07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com